NCT00159822

Voriconazole For Chronic Bronchopulmonary Aspergillosis

Voriconazole For Primary Therapy Of Proven, Chronic Bronchopulmonary Aspergillosis, In Minimally Immunocompromised Or, Non-Immunocompromised Hosts

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy of voriconazole (VFend(R)) as first line treatment for proven chronic bronchopulmonary aspergillosis, in minimally immunocompromised or non-immunocompromised patients after 6 months of treatment i.e. chronic necrotizing pulmonary

Conditions

• Aspergillosis

Interventions

Type	Name	Description
DRUG	Voriconazole	Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response. Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours

Timeline

• Start date: 2005-07-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2005-09-12
• Last updated: 2010-01-20
• Results posted: 2010-01-07

Locations

18 sites across 1 country: France